NewPeptide PenTriple Receptor Research Peptide
Free shipping over £138.25 · ships within 24h
TRUSTED BY RESEARCHERS
Triple-Receptor Action
GLP-1 + GIP + glucagon — the only peptide engaging all three incretin pathways for next-generation metabolic research
Most-Studied Tri-Incretin
Same compound from Eli Lilly's TRIUMPH phase-2 programme reporting record-breaking results
Full Titration Range
Adjustable pen dial covers 0.5 mg → 12 mg weekly without product waste
Once-Weekly Convenience
6-day half-life allows simple weekly dosing schedule
A triple receptor agonist (GLP-1 / GIP / Glucagon) investigated in early-phase metabolic research. Studies suggest Retatrutide may modulate appetite, glucose homeostasis, and energy expenditure through three independent incretin pathways. ORYN Retatrutide delivers 5mg/3ml in a reusable pen system with precision dosing for 30 days.
LEARN ABOUT THE RETATRUTIDE PEN FORMAT →GLP-1 + GIP + glucagon — the only peptide engaging all three incretin pathways for next-generation metabolic research
Same compound from Eli Lilly's TRIUMPH phase-2 programme reporting record-breaking results
Adjustable pen dial covers 0.5 mg → 12 mg weekly without product waste
6-day half-life allows simple weekly dosing schedule
Bacteriostatic water, syringe, precise mixing
Syringe markings can vary 10-20%
Rubber stopper punctured multiple times
Potency drops after reconstitution
5-10 minutes per preparation
Vials, syringes, water, needles...
Retatrutide research uses fine-grained weekly dose escalations (0.5 mg → 12 mg). The pen's adjustable dial covers the entire phase-2 range without product waste.
Triple-receptor agonists are structurally complex. The sealed pen cartridge protects the molecule from the reconstitution and oxidative steps that can degrade its tri-receptor activity.
Phase-2 protocols run 24-48 weeks. The pen format guarantees that dose 1 and dose 30 deliver the same molecule at the same purity — critical for longitudinal research data.
5 mg in one pen covers a full 30-day dose-escalation block, simplifying procurement for multi-month research programs.
Prep Time
Dose Accuracy
Sterility
Stability
Attach needle and prime with small test dose
Dial the prescribed weekly dose
Inject subcutaneously in the abdomen, thigh, or upper arm
Administer on the same day each week
Hold 10 seconds before removing to ensure full delivery
Rotate injection sites weekly
Always use a new sterile needle for each administration. Dispose of used needles in an appropriate sharps container. Store pen refrigerated at 2-8°C.
Triple GLP-1 / GIP / Glucagon Receptor Agonist
4,731.27 g/mol
Approximately 6 days
Retatrutide is the most extensively studied tri-incretin compound to date. It activates GLP-1, GIP, and glucagon receptors simultaneously — adding a glucagon-receptor arm to the dual mechanism of Tirzepatide. Early-phase research suggests this triple action may modulate appetite, glucose homeostasis, and energy expenditure through three independent incretin pathways at once.
First-in-human data confirmed safe activation of all three incretin receptors with dose-dependent metabolic responses.
Reported up to 24% body weight reduction at 48 weeks — the largest effect size observed for any incretin compound to date.
Significant reductions in liver fat content observed in metabolic dysfunction-associated steatotic liver research.
“Retatrutide's triple-receptor mechanism is a real step beyond Tirzepatide. The ORYN pen lets us run the full phase-2 escalation without juggling vials and dilutions.”
Dr. S. Hoffmann
Metabolic Research, Frankfurt
“Independent HPLC confirmed >99.3% purity on our first batch. The pen format makes the long titration window genuinely manageable for multi-month studies.”
Dr. T. Nilsson
Diabetes Research, Uppsala
“GLP-1 + GIP + glucagon all in one molecule, in a pen format that doesn't require redilution between weekly doses. Exactly what tri-incretin research needs.”
Dr. A. Dupont
Endocrinology Lab, Paris
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon receptors) while Tirzepatide is dual (GLP-1 + GIP). Adding glucagon-receptor activation may further increase energy expenditure and lipid mobilisation. Phase-2 trials reported up to 24% body weight reduction vs Tirzepatide's ~22.5%.
Join 3,000+ researchers. Monthly SOPs, new peptide launches, and a WELCOME10 code for your first order.
NO SPAM · UNSUBSCRIBE ANYTIME
COA included with every order. Batch-specific reports available on request.
See how ORYN pre-mixed peptide pens compare to traditional vials and other suppliers.
| Feature | ORYN Pens | Traditional Vials | Other Suppliers |
|---|---|---|---|
| Format | Pre-mixed pen | Lyophilised powder | Mixed |
| Purity | >99% verified | Variable (70-95%) | Claims vary |
| Dosing accuracy | <2% error | ~15% error | N/A |
| Reconstitution needed | No | Yes | Sometimes |
| Contamination risk | Sealed system | Multi-use vial | Varies |
| COA included | Every order | Rarely | Sometimes |
| GMP certified | Yes | Rarely | Some |
| EU customs-free | Yes | Often no | Varies |
This product is intended for laboratory and research purposes only. Not for human consumption.
Premium pen delivery system with fully adjustable dosing. GMP manufactured, >99% purity guaranteed.
Legal under MHRA rules. BPC-157, tirzepatide & NAD+ pens with next-day UK delivery from £99. >99% purity, GMP certified. Shop now.
ARTICLEPens cut dosing error from 15% to under 2%. We compare accuracy, contamination risk, cost, and convenience. See why researchers are switching in 2026.
ARTICLEOver 100 published studies back BPC-157 for tissue repair, gut healing, and neuroprotection. Mechanisms, dosing protocols, and where to buy in the UK.
COMPARISONCompare BPC-157 and TB-500 for recovery research. Mechanisms, benefits, dosing, and when to use each peptide. Buy both as pre-mixed pens UK.
COMPARISONCompare tirzepatide and semaglutide for metabolic research. Dual vs single receptor, efficacy data, side effects, and pricing. Buy tirzepatide pens UK.
ENCYCLOPEDIATriple Hormone Receptor Agonist (GIP/GLP-1/Glucagon). Molecular weight: 4611.09 Da. Explore mechanism of action, key studies, and research applications.
BUNDLEThe classic healing duo for accelerated tissue repair
PROTOCOLResearch protocol combining BPC-157 and TB-500 peptide pens for accelerated tissue recovery. Explore synergistic healing mechanisms, dosing schedules, and published study findings.
FAQEverything you need to know about peptide pen systems. Learn how pre-mixed peptide pens work, their advantages over vials, dosing mechanisms, and more.
CATEGORYResearch-grade recovery peptide pens. BPC-157 and TB-500 for tissue repair, wound healing, and inflammation research. >99% purity, UK delivery.
CATEGORYResearch-grade weight loss peptide pens. Tirzepatide dual GIP/GLP-1 agonist for metabolic research. Pre-mixed pens, >99% purity, next-day UK delivery.
